Veeral Sheth, MD, MBA, FAS, FASRS

Gene therapy offers a promising alternative by potentially providing long-lasting effects from a single treatment.

Real-world patients often fail to achieve and retain the visual acuity results observed in clinical trials for anti–VEGF-A therapy. Broader therapeutic inhibition of additional angiogenic factors VEGF-C and VEGF-D could change that.